The Federal Trade Commission said the deal would enable Amgen to “entrench” the monopoly positions of two Horizon drugs that lack competition.
U.S. Sues to Block Amgen’s $27.8 Billion Takeover of Horizon Therapeutics
Written by
in
The Federal Trade Commission said the deal would enable Amgen to “entrench” the monopoly positions of two Horizon drugs that lack competition.
Written by
in